At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 506 enrolled
Drug / intervention
Twinrix +4 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Challenge Dose Administration of Twinrix™ or Comparator 4 Years After Primary Vaccination.
In Brief
A Phase 4 clinical trial evaluating Twinrix, Engerix-B, and 3 other interventions for Hepatitis A and Hepatitis B. Completed, enrolled 506 participants across 2 sites in 2 countries.
Detailed Summary
Only subjects who participated in the primary study will be invited to participate in the extension phase and the challenge dose phase of this study.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatitis A, Hepatitis B
CountriesBelgium, Czechia
Collaborators--
Timeline
Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMay 2008
First PostedMay 2008
Primary CompletionNov 2008
TodayJul 2026
First PostedMay 28, 2008
Enrollment StartMay 26, 2008
Primary CompletionNov 3, 2008
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 18.1 years ago
Interventions
Twinrixbiological
Intramuscular injection, single dose in left deltoid.
Engerix-Bbiological
Intramuscular injection, single dose in left deltoid.
Havrixbiological
Intramuscular injection, single dose in right deltoid.
HBVAXPRObiological
Intramuscular injection, single dose in the left deltoid.
Vaqtabiological
Intramuscular injection, single dose in right deltoid.